These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 32096839)

  • 21. Reduction of No Reflow with a Loading Dose of Atorvastatin before Primary Angioplasty in Patients with Acute ST Myocardial Infarction.
    García-Méndez RC; Almeida-Gutierrez E; Serrano-Cuevas L; Sánchez-Díaz JS; Rosas-Peralta M; Ortega-Ramirez JA; Palomo-Villada JA; Isordia-Salas I; Alonso-Bravo RM; Borrayo-Sanchez G
    Arch Med Res; 2018 Nov; 49(8):620-629. PubMed ID: 30446246
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of High-Dose Atorvastatin Reload on the Release of Endothelial Progenitor Cells in Patients on Long-Term Statin Treatment Who Underwent Percutaneous Coronary Intervention (from the ARMYDA-EPC Study).
    Ricottini E; Madonna R; Grieco D; Zoccoli A; Stampachiacchiere B; Patti G; Tonini G; De Caterina R; Di Sciascio G
    Am J Cardiol; 2016 Jan; 117(2):165-71. PubMed ID: 26743348
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy of high-dose atorvastatin loading before primary percutaneous coronary intervention in ST-segment elevation myocardial infarction: the STATIN STEMI trial.
    Kim JS; Kim J; Choi D; Lee CJ; Lee SH; Ko YG; Hong MK; Kim BK; Oh SJ; Jeon DW; Yang JY; Cho JR; Lee NH; Cho YH; Cho DK; Jang Y
    JACC Cardiovasc Interv; 2010 Mar; 3(3):332-9. PubMed ID: 20298994
    [TBL] [Abstract][Full Text] [Related]  

  • 24. What Is the Appropriate Duration of High-Dose Atorvastatin Therapy Post-Acute Coronary Syndrome?
    Goriacko P; Andersen M; Fazylov R; Plakogiannis R
    J Pharm Pract; 2015 Dec; 28(6):555-60. PubMed ID: 25107416
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Usefulness of Elevated Levels of Growth Differentiation Factor-15 to Classify Patients With Acute Coronary Syndrome Having Percutaneous Coronary Intervention Who Would Benefit from High-Dose Statin Therapy.
    Tentzeris I; Farhan S; Freynhofer MK; Rohla M; Jarai R; Vogel B; Baumgartner-Parzer S; Nürnberg M; Geppert A; Wessely E; Wojta J; Huber K; Kautzky-Willer A
    Am J Cardiol; 2017 Sep; 120(5):747-752. PubMed ID: 28734463
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Therapeutic effects of atorvastatin and ezetimibe compared with double-dose atorvastatin in very elderly patients with acute coronary syndrome.
    Liu Z; Hao H; Yin C; Chu Y; Li J; Xu D
    Oncotarget; 2017 Jun; 8(25):41582-41589. PubMed ID: 28177908
    [TBL] [Abstract][Full Text] [Related]  

  • 27. High-dose statin pretreatment decreases periprocedural myocardial infarction and cardiovascular events in patients undergoing elective percutaneous coronary intervention: a meta-analysis of twenty-four randomized controlled trials.
    Wang L; Peng P; Zhang O; Xu X; Yang S; Zhao Y; Zhou Y
    PLoS One; 2014; 9(12):e113352. PubMed ID: 25473831
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Early, intensive statin treatment reduces 'hard' cardiovascular outcomes after acute coronary syndrome.
    Schwartz GG; Fayyad R; Szarek M; DeMicco D; Olsson AG
    Eur J Prev Cardiol; 2017 Aug; 24(12):1294-1296. PubMed ID: 28504565
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of intensive statin therapy on regression of coronary atherosclerosis in patients with acute coronary syndrome: a multicenter randomized trial evaluated by volumetric intravascular ultrasound using pitavastatin versus atorvastatin (JAPAN-ACS [Japan assessment of pitavastatin and atorvastatin in acute coronary syndrome] study).
    Hiro T; Kimura T; Morimoto T; Miyauchi K; Nakagawa Y; Yamagishi M; Ozaki Y; Kimura K; Saito S; Yamaguchi T; Daida H; Matsuzaki M;
    J Am Coll Cardiol; 2009 Jul; 54(4):293-302. PubMed ID: 19608026
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of High-Dose Statin Pretreatment for Myocardial Perfusion in Patients Receiving Percutaneous Coronary Intervention (PCI): A Meta-Analysis of 15 Randomized Studies.
    Xiao Y; He S; Zhang Z; Feng H; Cui S; Wu J
    Med Sci Monit; 2018 Dec; 24():9166-9176. PubMed ID: 30557296
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rationale and design of the Statins Evaluation in Coronary procedUres and REvascularization: The SECURE-PCI Trial.
    Berwanger O; de Barros E Silva PGM; Dall Orto FTC; de Andrade PB; de Castro Bienert IR; Bosso CE; Mangione J; Polanczyk CA; Sousa A; Kalil R; de Moura Santos L; Sposito AC; Rech RL; Sousa ACS; Baldissera F; Nascimento BR; de Andrade Jesuíno I; Santucci EV; Damiani LP; Laranjeira LN; Borges de Oliveira JA; Giraldez RR; Cavalcanti AB; Pereira SB; Mattos LA; Armaganijan LV; Guimarães HP; Sousa JE; Alexander JH; Granger CB; Lopes RD
    Am Heart J; 2018 Apr; 198():129-134. PubMed ID: 29653634
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Influence of high-dose highly efficient statins on short-term mortality in patients undergoing percutaneous coronary intervention with stenting for acute coronary syndromes.
    Berent R; Berent T; Karkutli E; Sinzinger H
    Am J Cardiol; 2014 Oct; 114(7):1128-9. PubMed ID: 25212554
    [No Abstract]   [Full Text] [Related]  

  • 33. Short-term, high-dose Atorvastatin pretreatment to prevent contrast-induced nephropathy in patients with acute coronary syndromes undergoing percutaneous coronary intervention (from the ARMYDA-CIN [atorvastatin for reduction of myocardial damage during angioplasty--contrast-induced nephropathy] trial.
    Patti G; Ricottini E; Nusca A; Colonna G; Pasceri V; D'Ambrosio A; Montinaro A; Di Sciascio G
    Am J Cardiol; 2011 Jul; 108(1):1-7. PubMed ID: 21529740
    [TBL] [Abstract][Full Text] [Related]  

  • 34. High-dose atorvastatin in acute coronary and cerebrovascular syndromes.
    Lavie CJ; Milani RV
    JACC Cardiovasc Interv; 2010 Mar; 3(3):340-2. PubMed ID: 20298995
    [No Abstract]   [Full Text] [Related]  

  • 35. High dose statin loading prior to percutaneous coronary intervention decreases cardiovascular events: a meta-analysis of randomized controlled trials.
    Benjo AM; El-Hayek GE; Messerli F; DiNicolantonio JJ; Hong MK; Aziz EF; Herzog E; Tamis-Holland JE
    Catheter Cardiovasc Interv; 2015 Jan; 85(1):53-60. PubMed ID: 24272891
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Utility of early high dose statins in acute coronary syndrome.
    Dougherty PJ; Arora RR
    Am J Ther; 2012 Sep; 19(5):369-76. PubMed ID: 22964560
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Reduction in recurrent cardiovascular events with intensive lipid-lowering statin therapy compared with moderate lipid-lowering statin therapy after acute coronary syndromes from the PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) trial.
    Murphy SA; Cannon CP; Wiviott SD; McCabe CH; Braunwald E
    J Am Coll Cardiol; 2009 Dec; 54(25):2358-62. PubMed ID: 20082923
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prescription of statins after acute coronary syndrome; a single-centre observational study.
    Mahmood MM; Nawaz MJ
    J Pak Med Assoc; 2023 Mar; 73(3):646-649. PubMed ID: 36932772
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Triglyceride-Rich Lipoprotein Cholesterol and Risk of Cardiovascular Events Among Patients Receiving Statin Therapy in the TNT Trial.
    Vallejo-Vaz AJ; Fayyad R; Boekholdt SM; Hovingh GK; Kastelein JJ; Melamed S; Barter P; Waters DD; Ray KK
    Circulation; 2018 Aug; 138(8):770-781. PubMed ID: 29618599
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Meta-analysis of short-term high versus low doses of atorvastatin preventing contrast-induced acute kidney injury in patients undergoing coronary angiography/percutaneous coronary intervention.
    Wu H; Li D; Fang M; Han H; Wang H
    J Clin Pharmacol; 2015 Feb; 55(2):123-31. PubMed ID: 25310898
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.